Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant fundraises and strategic collaborations Corporate focus on delivering top-line results from the pivotal Phase 2b clinical trial in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 Than Powell stepped down as interim CEO; will remain with the Company to support the lea

Telomeres are protective structures located at the ends of chromosomes, helping preserve genetic stability during cell division. As cells undergo repeated cycles of division, telomere length gradually changes, and this characteristic has been widely recognized as closely associated with aging and shifts in cellular function. As research continues to reveal strong links between telomere dynamics and the biological mechanisms of aging as well as various diseases, telomere extension technology has

AI is transforming healthcare by augmenting clinical decision-making, automating administrative tasks and accelerating drug discovery This week's top healthcare stories include McKinsey's use of tech and AI, GSK's new CEO and dsm-firmenich's updated focus on its health and beauty sectors McKinsey: Reshaping US Healthcare With Technology and AI McKinsey released its "What to expect in US healthcare in 2026 and beyond" report, delivering a stark assessment of the sector's trajectory. The findings

In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended 1 Results favored Vanrafia across multiple timepoints, measures of kidney function and in patients additionally receiving SGLT2 inhibitors 1 Vanrafia received accelerated approval in U.S. and China for reduction of proteinuria in adults with IgAN in 2025; Novartis plans to submit for traditional approval in 2026 2 Basel, February 13, 2026 –

FRIDAY, Feb. 13, 2026 -- The increased number of state-level abortion restrictions in the United States from 2005 to 2023 was associated with an increase in maternal deaths, according to a study presented at The Pregnancy Meeting, the annual meeting of the Society for Maternal-Fetal Medicine, held from Feb. 8 to 13 in Las Vegas. Marie C. Anderson, M.D., from Columbia University in New York City, and colleagues investigated the effect of state-level abortion restrictions on maternal deaths in th

FRIDAY, Feb. 13, 2026 -- Reinstating Medicare's three-day hospitalization requirement was associated with longer inpatient stays, with no change in skilled nursing facility (SNF) utilization, according to a study published online Feb. 9 in JAMA Internal Medicine . Zihan Chen, M.P.P., from the Brown University School of Public Health in Providence, Rhode Island, and colleagues conducted a retrospective cohort study of Medicare beneficiaries with acute care hospitalizations to examine changes in a

iStock, Jian Fan Analysts are keeping a close eye on Vertex’s kidney disease portfolio, anchored by the IgAN drug povetacicept, as its nonopioid painkiller Journavx is poised for “incremental” growth in the first half 2026, according to BMO Capital Markets. Vertex Pharmaceuticals’ late-stage study of povetacicept in IgA nephropathy has a “clean bill of health so far,” building up to a highly anticipated readout in the first half of this year as the biotech continues to slowly accrue sales for i

European Commission grants approval for Gotenfia ® , a golimumab biosimilar to Simponi ® that was developed by Bio-Thera and will be marketed by STADA Launch preparations are underway to bring the second approved golimumab biosimilar to patients across Europe in the coming weeks and months Bio-Thera is responsible for development, manufacture and supply; STADA for commercialization in the EU, the UK, Switzerland and selected other countries BAD VILBEL, Germany and GUANGZHOU, China , Feb. 13, 2

FRIDAY, Feb. 13, 2026 — Doctors could reduce rates of a dangerous high blood pressure condition in pregnancy by taking one simple step, a new study says. Prescribing daily aspirin to all pregnant women at their first prenatal visit was associated with an overall reduction in cases of severe preeclampsia , according to findings presented at a meeting of the Society for Maternal-Fetal Medicine in Las Vegas. “Implementation of directly-dispensed aspirin in this high-risk pregnant population appear

Today, a brief rundown of news from Lyell Immunopharma and Biogen as well as updates from the European Life Sciences Coalition and Novocure that you may have missed.Lyell Immunopharma said Thursday it has begun dosing patients in a first-of-its-kind Phase 3 trial testing ronde-cel, an experimental, dual-acting cancer cell therapy, directly against an investigators choice of approved CAR-T treatments for large B-cell lymphoma. The trial is expected to enroll 400 people whose lymphoma relapsed or